Supreme Pharmaceuticals (CSE: SL) New Listing

I’m Samantha Deutscher for Investmentpitch
media Supreme Pharmaceuticals is one of the latest
new listings on the Canadian Securities Exchange, and is trading under the symbol “SL”. The company stated that its move from the
TSX Venture Exchange will allow it to efficiently and seamlessly transition from a junior resource
company to one whose main focus is now on the emerging medical marijuana field. President and CEO, David Stadnyk stated: “Our
goal is to secure several medical marijuana producing facilities, each with a MMPR license. There is no assurance that we will be able
to secure such facilities. This is a critical year for MMPR licences
and we plan on making several applications to Health Canada.” “While we have longstanding relationships
with both the TSX Venture and the Canadian Securities Exchange, we believe this is the
right move for the Company at this time. We now have two producing medical marijuana
facilities under evaluation and expect to report positive news shortly.” The company has already signed a conditional
agreement with an arms-length South Okanagan-based company giving Supreme the option to purchase
its producing medical marijuana business. The company, which until recently operated
as Supreme Resources under the symbol SPR, would appear to be better suited that most
companies to make this switch, as the current management team has a track record of finding
and developing early stage pharmaceutical or biomedical device companies. The company also announced it has no plans
to dispose of or shelve its mineral exploration properties, and will continue to work on them
as the opportunities present themselves. In September 2013, the company closed a private
placement consisting of 79.9 million units $0.005, which contained a warrant to purchase
a common share at $0.05 for a period of 12 months. The recent increase in the share price has
facilitated the exercise of a significant number of these warrants, which allowed the
company to cancel its recently announced private placement. The shares are trading at $0.055, and with
145 million shares outstanding, the company is capitalized at $8 million. For more information, please visit the company’s
website, www.supremepharmaceuticals.com or contact David Stadnyk, President & CEO, at
647-340-6744 or email [email protected] I’m Samantha Deutscher for Investmentpitch
media For more video news, and to view our disclaimer,
please visit our website at www.investmentpitch.com This video is for information purposes only
and it not a recommendation to buy or sell any securities.

1 comment

Leave a Reply

(*) Required, Your email will not be published